The 4th China-Europe Symposium on Biomaterials in Regenerative Medicine (CESB2013) was held in Sorrento Italy, on July 1-4, 2013. Prof. Aiguo Wu from NIMTE was invited to give an oral presentation at this conference and act as a session Chairman.

Chinese Society of Biomaterials signed the agreement with European Society of Biomaterials to organize the China-Europe Symposium on Biomaterials every two years. Since its establishment in 2006, this biennial symposium has been held on three occasions including Suzhou (China), Barcelona (Spaim) and Nanjing (China).

The endowment of biomaterials with biological structure and biological function, thereby regenerating or reconstructing a seriously diseased tissue or organ, has been the priority of biomaterials science and engineering throughout this century, and will undoubtedly lead to a significant breakthrough. This breakthrough will come from the integration of materials science with modern biology and biological technology – in particular, with molecular biology, tissue engineering, stem cell technology and related disciplines. These areas of endeavour and pioneering concepts which integrate materials science and pre-clinical validation were discussed in the CESB2013. The CESB2013 reflected the developmental trend and the progress on the frontier research of biomaterials science and engineering, including progress in clinical research and its applications, particularly in China and Europe. This will undoubtedly further promote and stimulate the growth of Chinese-European communities in Biomaterials Science.

Prof. Aiguo Wu, group leader of the Nano Biomaterials Research Group (Group Url: http://nano.nimte.ac.cn/pages/wuaiguo/en/index-En.htm ), gave a presentation in the conference entitled “Applications of Metal Oxides-based Nanoparticles in Biomedical Imaging, Targeting Drug Delivery and Overcoming Multidrug Resistance”. In his presentation, Prof. Aiguo Wu showed the new data from his research group, including metal oxides-based nanoparticles as imaging agents and therapeutic agents of cancer cells, or drug carriers overcoming multidrug resistance in human breast cancer cells, or drug delivery systems with tumor targetability.

(Zheyu Shen reports.)